Recently, an investigation reported that combining PKI-587 with Cofetuzumab Pelidotin, a protein tyrosine kinase 7 (PTK7)-targeted, auristatin-based antibody-drug conjugate in patients with metastatic triple-negative breast cancer (TNBC) was associated with promising clinical activity, two months median PFS, and moderate toxicity (anorexia nausea, mucositis, and fatigue) [107]. The gene discussed is PTK7; the disease is triple-negative breast carcinoma.